The North Carolina Business Court recently made significant rulings in the case of Gaston Capital, LLC v. Kellar, 25-CVS-6056. This case involves a dispute between private equity companies and a medical device engineer, affecting over $10 million in loans. The court's decisions will shape how similar investment disputes are handled in the future.
The case centers around a series of loans made by Gaston Capital and its associated funds to Franz Kellar and his companies, which develop biomedical devices. The loans were intended to fund the development of medical devices for ligament repair. However, the plaintiffs allege that Kellar mismanaged the funds and transferred intellectual property rights to other entities, leaving them unable to recover their investments.
The plaintiffs, including Gaston Capital and several associated funds, initiated the lawsuit in October 2025, claiming breach of contract, fraud, and other related offenses. The case was designated as a complex business case and assigned to Judge Mark A. Davis. The defendants, led by Kellar, filed a partial motion to dismiss the plaintiffs' claims in January 2026, arguing that many claims were time-barred or lacked sufficient legal basis.
During the proceedings, the court addressed two main motions: the defendants' motion to dismiss certain claims and the plaintiffs' motion to amend their complaint to include additional defendants. The court ruled on these motions in a combined opinion issued on July 30, 2026.
In the ruling, the court granted the defendants' motion to dismiss several claims, including breach of fiduciary duty, fraudulent misrepresentation, and constructive fraud. Specifically, the court found that the plaintiffs had failed to establish a fiduciary relationship with the defendants, which is necessary for such claims. Judge Davis stated, "The mere existence of a debtor-creditor relationship between the parties does not create a fiduciary relationship."
Additionally, the court dismissed portions of the breach of contract claims based on the statute of limitations, which bars claims filed after a certain period. The court noted that some promissory notes involved in the case had maturity dates that exceeded the three-year limit for filing such claims. However, the court allowed some breach of contract claims to proceed, particularly those with waiver language that could extend the statute of limitations.
On the other hand, the court granted the plaintiffs' motion to amend their complaint, allowing them to add new defendants to the case. This amendment is significant as it expands the scope of the lawsuit and could potentially increase the plaintiffs' chances of recovering their investments.
The court's ruling has far-reaching implications for private equity firms and investors in the biomedical sector. It emphasizes the importance of clear contractual agreements and the need for investors to be vigilant about the management of their funds. The decision also highlights the challenges faced by investors when dealing with claims of fraud and misrepresentation.
Moving forward, the case will continue as the plaintiffs file their amended complaint, which is due by August 5, 2026. The defendants may also consider their options for appeal regarding the court's rulings. This case serves as a reminder for investors to thoroughly vet their agreements and ensure that they have adequate protections in place when entering into financial arrangements.
Overall, the Gaston Capital v. Kellar case illustrates the complexities of investment disputes in the biomedical field and the legal standards that courts apply when evaluating claims of fraud and breach of contract.